Evidence map›Paper›PMID 29333958›Full record

ArticleTechnology in cancer research & treatment2017

Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.

Metha Maenhout, Max Peters, Marco van Vulpen, Marinus A Moerland, Richard P Meijer, Maurice A A J van den Bosch, Paul L Nguyen, Steven J Frank, Jochem R N van der Voort van Zyp

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Metha Maenhout1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
Max Peters1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
Marco van Vulpen2 Department of Urology, University Medical Center Utrecht, Utrecht, the Netherlands.
Marinus A Moerland1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
Richard P Meijer1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
Maurice A A J van den Bosch1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.
Paul L Nguyen3 Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Steven J Frank4 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jochem R N van der Voort van Zyp1 Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhole-gland salvage treatment of radiorecurrent prostate cancer has a high rate of severe toxicity. The standard of care in case of a biochemical recurrence is androgen deprivation treatment, which is associated with morbidity and negative effects on quality of life. A salvage treatment with acceptable toxicity might postpone the start of androgen deprivation treatment, might have a positive influence on the patients' quality of life, and might even be curative. Here, toxicity and biochemical outcome are described after magnetic resonance imaging-guided focal salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer. MATERIALS AND

methodsSeventeen patients with pathologically proven locally recurrent prostate cancer were treated with focal high-dose-rate brachytherapy in a single 19-Gy fraction using magnetic resonance imaging for treatment guidance. Primary radiotherapy consisted of external beam radiotherapy or low-dose-rate brachytherapy. Tumors were delineated with Ga-68-prostate-specific membrane antigen or F18-choline positron emission tomography in combination with multiparametric magnetic resonance imaging. All patients had a prostate-specific antigen level of less than 10 ng/mL at the time of recurrence and a prostate-specific antigen doubling time of ≥12 months. Toxicity was measured by using the Common Terminology Criteria for Adverse Events version 4.

resultsEight of 17 patients had follow-up interval of at least 1 year. At a median follow-up interval of 10 months (range 3-40 months), 1 patient experienced a biochemical recurrence according to the Phoenix criteria, and prostate-specific membrane antigen testing revealed that this was due to a distant nodal metastasis. One patient had a grade 3 urethral stricture at 2 years after treatment.

conclusionFocal salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer showed grade 3 toxicity in 1 of 17 patients and a distant nodal metastasis in another patient. Whether this treatment option leads to cure in a subset of patients or whether it can successfully postpone androgen deprivation treatment needs further investigation.

Indexed as

AgedAged, 80 and overAntigens, SurfaceBrachytherapyGallium RadioisotopesGlutamate Carboxypeptidase IIHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstateProstatic NeoplasmsRadiation InjuriesRadiotherapy DosageSalvage TherapyAntigens, SurfaceFOLH1 protein, humanGallium-68Gallium RadioisotopesGlutamate Carboxypeptidase IIfocal treatmentHDR brachytherapyMRI guidancerecurrent prostate cancersalvage treatment

Identifiers

PMID29333958
PMCPMC5762090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.